MacroGenics, Inc. (MGNX) News

MacroGenics, Inc. (MGNX): $4.31

0.18 (+4.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MGNX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 391

in industry

Filter MGNX News Items

MGNX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest MGNX News From Around the Web

Below are the latest news stories about Macrogenics Inc that investors may wish to consider to help them evaluate MGNX as an investment opportunity.

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March 2022: Cowen 42nd Annual Health Care Conference. MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate on the Gastrointestinal/Ge

Yahoo | March 3, 2022

What 4 Analyst Ratings Have To Say About Macrogenics

Analysts have provided the following ratings for Macrogenics (NASDAQ: MGNX ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 3 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Macrogenics. The company has an average price target of $28.75 with a high of $40.00 and a low of $21.00. Below is a summary of how these 4 analysts rated Macrogenics over the past 3 months. The greater the number of bullish ratings, … Full story available on Benzinga.com

Benzinga | February 28, 2022

MacroGenics upgraded to buy at Citi on valuation

Citi has upgraded MacroGenics (MGNX) to buy from neutral saying the company''s pipeline has "entered undervalued territory."

Seeking Alpha | February 28, 2022

MacroGenics Announces Executive Promotion

ROCKVILLE, MD, Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced today that it has promoted Eric Risser to Chief Operating Officer, as of February 22. Mr. Risser joined MacroGenics in 2009 and has played an instrumental leadership role in sourcing, structuring and negotiating the company's collaboration partnerships and has been res

Yahoo | February 28, 2022

MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials

No summary available.

Seeking Alpha | February 25, 2022

Why MacroGenics Stock Is Sinking Today

The company provided a disappointing Q4 update.

The Motley Fool | February 25, 2022

MacroGenics (MGNX) Q4 2021 Earnings Call Transcript

MGNX earnings call for the period ending December 31, 2021.

The Motley Fool | February 25, 2022

MacroGenics Provides Update on Corporate Progress and 2021 Financial Results

ROCKVILLE, Md., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2021.

GlobeNewswire | February 24, 2022

MacroGenics, Inc. (MGNX) CEO Scott Canning on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 24, 2022

MacroGenics GAAP EPS of -$3.37 misses by $0.10, revenue of $77.45M misses by $6.13M

MacroGenics press release (MGNX): FY GAAP EPS of -$3.37 misses by $0.10.Revenue of $77.45M (-26.2% Y/Y) misses by $6.13M.

Seeking Alpha | February 24, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6097 seconds.